Related Experiment Videos
Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge
G Ciprandi1, S Buscaglia, C Pronzato
1Medical Department, Puropharma, Milan, Italy.
Summary
Oxatomide effectively reduces allergic eye inflammation and cellular responses in patients with rhinoconjunctivitis. This study confirms oxatomide
Area of Science:
- Ophthalmology
- Allergology
- Pharmacology
Background:
- Allergen-specific conjunctival challenge is a validated model for assessing allergic disease treatments.
- Evaluating drug efficacy and mechanisms in allergic conjunctivitis requires robust experimental models.
Purpose of the Study:
- To assess the protective effect of oxatomide against inflammatory changes post-allergen challenge.
- To evaluate oxatomide's impact on cellular responses, including ICAM-1 expression, in allergic rhinoconjunctivitis.
Main Methods:
- A double-blind study involving 20 patients with Parietaria judaica-induced rhinoconjunctivitis.
- Patients received either 60 mg daily oral oxatomide or placebo for seven days.
- Clinical and cytologic assessments (inflammatory cells, ICAM-1) were performed at multiple time points post-challenge, before and after treatment.
Main Results:
- Oxatomide significantly reduced clinical events in both early and late allergic phase reactions compared to placebo.
- Total inflammatory cell counts and ICAM-1 expression on epithelial cells were significantly decreased by oxatomide.
- No adverse cardiac events were observed, indicating a favorable safety profile.
Conclusions:
- Oxatomide demonstrates significant protective effects on clinical and cellular responses in allergen-induced conjunctival challenge.
- The drug effectively mitigates both early and late-phase allergic reactions, including ICAM-1 expression.
- Oxatomide is confirmed to be safe and well-tolerated for treating allergic rhinoconjunctivitis.